Real life outcome analysis of breast cancer brain metastases treated with Trastuzumab Deruxtecan
Abstract Tumor dissemination to the central nervous system (CNS) is almost a rule in the treatment journey of advanced HER2+ breast cancer (BC). Recent results demonstrated high intracranial efficacy with Trastuzumab Deruxtecan (T-DXd). However, a real-world evidence is lacking in literature. We con...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2025-01-01
|
| Series: | npj Precision Oncology |
| Online Access: | https://doi.org/10.1038/s41698-025-00801-3 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832586062543716352 |
|---|---|
| author | Alessandra Fabi Alessandro Rossi Roberta Caputo Simona Pisegna Simone Scagnoli Francesco Pantano Giuliana D’Auria Palma Fedele Agnese Fabbri Claudio Vernieri Michela Palleschi Luisa Carbognin Gianluigi Ferretti Elena Di Monte Ida Paris Francesco Pavese Ornella Garrone Antonio Franco Michelino De Laurentiis Gianluca Franceschini Giovanni Scambia Diana Giannarelli Riccardo Masetti Andrea Botticelli |
| author_facet | Alessandra Fabi Alessandro Rossi Roberta Caputo Simona Pisegna Simone Scagnoli Francesco Pantano Giuliana D’Auria Palma Fedele Agnese Fabbri Claudio Vernieri Michela Palleschi Luisa Carbognin Gianluigi Ferretti Elena Di Monte Ida Paris Francesco Pavese Ornella Garrone Antonio Franco Michelino De Laurentiis Gianluca Franceschini Giovanni Scambia Diana Giannarelli Riccardo Masetti Andrea Botticelli |
| author_sort | Alessandra Fabi |
| collection | DOAJ |
| description | Abstract Tumor dissemination to the central nervous system (CNS) is almost a rule in the treatment journey of advanced HER2+ breast cancer (BC). Recent results demonstrated high intracranial efficacy with Trastuzumab Deruxtecan (T-DXd). However, a real-world evidence is lacking in literature. We conducted a multicenter, observational, retrospective real-world analysis on 39 cases collected at 12 Italian Oncological Units. Patients with brain metastases (BMs) from HER2 + BC treated with T-DXd in various treatment lines were enrolled. Primary endpoint was the intracranial overall response rate (iORR). Secondary endpoints were intra- and global progression free survival (iPFS - gPFS); other secondary objectives were the intracranial disease control rate (iDCR), duration of response (iDoR), clinical benefit rate at 6 and 12 months (iCBr), overall survival, and safety. iORR was 59%, iPFS was 15.6 months, gPFS was 11.8 months. iDCR was 94.9%, iDoR was 11.9 months, and iCBr at 6 and 12 months were 69.2% and 59%, respectively. OS was not reached, with an overall rate of 77.9% of patients alive at 12 months. This study confirmed the high intracranial efficacy and manageable safety profile of T-DXd in this first-ever real world analysis. |
| format | Article |
| id | doaj-art-6f32ae93174d43c79939836881f5dd0d |
| institution | Kabale University |
| issn | 2397-768X |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | npj Precision Oncology |
| spelling | doaj-art-6f32ae93174d43c79939836881f5dd0d2025-01-26T12:12:52ZengNature Portfolionpj Precision Oncology2397-768X2025-01-01911810.1038/s41698-025-00801-3Real life outcome analysis of breast cancer brain metastases treated with Trastuzumab DeruxtecanAlessandra Fabi0Alessandro Rossi1Roberta Caputo2Simona Pisegna3Simone Scagnoli4Francesco Pantano5Giuliana D’Auria6Palma Fedele7Agnese Fabbri8Claudio Vernieri9Michela Palleschi10Luisa Carbognin11Gianluigi Ferretti12Elena Di Monte13Ida Paris14Francesco Pavese15Ornella Garrone16Antonio Franco17Michelino De Laurentiis18Gianluca Franceschini19Giovanni Scambia20Diana Giannarelli21Riccardo Masetti22Andrea Botticelli23Precision Medicine In Senology Unit, Fondazione Policlinico Universitario A. Gemelli IRCCSPrecision Medicine In Senology Unit, Fondazione Policlinico Universitario A. Gemelli IRCCSDepartment Of Breast And Thoracic Oncology, Division Of Breast Medical Oncology, Istituto Di Ricovero E Cura A Carattere Scientifico (IRCCS) PascaleDepartment Of Experimental Medicine, Sapienza University Of RomeDepartment Of Experimental Medicine, Sapienza University Of RomeMedical Oncology, Fondazione Policlinico Universitario Campus Bio-MedicoDepartment Of Medical Oncology, Sandro Pertini HospitalOncology Unit, Dario Camberlingo Hospital, Francavilla FontanaDepartment Of Oncology And Hematology, Medical Oncology And Breast Unit, Central Hospital Of BelcolleDepartment Of Medical Oncology, Fondazione Irccs Istituto Nazionale Dei TumoriIRCCS Istituto Romagnolo Per Lo Studio Dei Tumori “Dino Amadori” IrstPrecision Medicine In Senology Unit, Fondazione Policlinico Universitario A. Gemelli IRCCSMedical Oncology, Regina Elena National Cancer Institute RomeDepartment Of Medical Oncology, Comprehensive Cancer Center, Fondazione Policlinico Universitario Agostino Gemelli, IRCCSDepartment Of Woman And Child Health, Fondazione Policlinico Universitario A. Gemelli IRCCSDepartment Of Woman And Child Health, Fondazione Policlinico Universitario A. Gemelli IRCCSOncology Unit, Fondazione IRCCS Ca’ Granda Ospedale Maggiore PoliclinicoBreast Unit, Department Of Woman And Child’s Health And Public Health, Fondazione Policlinico Universitario A. Gemelli IrccsDepartment Of Breast And Thoracic Oncology, Division Of Breast Medical Oncology, Istituto Di Ricovero E Cura A Carattere Scientifico (IRCCS) PascaleBreast Unit, Department Of Woman And Child’s Health And Public Health, Fondazione Policlinico Universitario A. Gemelli IrccsDepartment Of Woman And Child Health, Fondazione Policlinico Universitario A. Gemelli IRCCSFacility Of Epidemiology And Biostatistics, Fondazione Policlinico Universitario A. Gemelli IRCCSBreast Unit, Department Of Woman And Child’s Health And Public Health, Fondazione Policlinico Universitario A. Gemelli IrccsDepartment Of Experimental Medicine, Sapienza University Of RomeAbstract Tumor dissemination to the central nervous system (CNS) is almost a rule in the treatment journey of advanced HER2+ breast cancer (BC). Recent results demonstrated high intracranial efficacy with Trastuzumab Deruxtecan (T-DXd). However, a real-world evidence is lacking in literature. We conducted a multicenter, observational, retrospective real-world analysis on 39 cases collected at 12 Italian Oncological Units. Patients with brain metastases (BMs) from HER2 + BC treated with T-DXd in various treatment lines were enrolled. Primary endpoint was the intracranial overall response rate (iORR). Secondary endpoints were intra- and global progression free survival (iPFS - gPFS); other secondary objectives were the intracranial disease control rate (iDCR), duration of response (iDoR), clinical benefit rate at 6 and 12 months (iCBr), overall survival, and safety. iORR was 59%, iPFS was 15.6 months, gPFS was 11.8 months. iDCR was 94.9%, iDoR was 11.9 months, and iCBr at 6 and 12 months were 69.2% and 59%, respectively. OS was not reached, with an overall rate of 77.9% of patients alive at 12 months. This study confirmed the high intracranial efficacy and manageable safety profile of T-DXd in this first-ever real world analysis.https://doi.org/10.1038/s41698-025-00801-3 |
| spellingShingle | Alessandra Fabi Alessandro Rossi Roberta Caputo Simona Pisegna Simone Scagnoli Francesco Pantano Giuliana D’Auria Palma Fedele Agnese Fabbri Claudio Vernieri Michela Palleschi Luisa Carbognin Gianluigi Ferretti Elena Di Monte Ida Paris Francesco Pavese Ornella Garrone Antonio Franco Michelino De Laurentiis Gianluca Franceschini Giovanni Scambia Diana Giannarelli Riccardo Masetti Andrea Botticelli Real life outcome analysis of breast cancer brain metastases treated with Trastuzumab Deruxtecan npj Precision Oncology |
| title | Real life outcome analysis of breast cancer brain metastases treated with Trastuzumab Deruxtecan |
| title_full | Real life outcome analysis of breast cancer brain metastases treated with Trastuzumab Deruxtecan |
| title_fullStr | Real life outcome analysis of breast cancer brain metastases treated with Trastuzumab Deruxtecan |
| title_full_unstemmed | Real life outcome analysis of breast cancer brain metastases treated with Trastuzumab Deruxtecan |
| title_short | Real life outcome analysis of breast cancer brain metastases treated with Trastuzumab Deruxtecan |
| title_sort | real life outcome analysis of breast cancer brain metastases treated with trastuzumab deruxtecan |
| url | https://doi.org/10.1038/s41698-025-00801-3 |
| work_keys_str_mv | AT alessandrafabi reallifeoutcomeanalysisofbreastcancerbrainmetastasestreatedwithtrastuzumabderuxtecan AT alessandrorossi reallifeoutcomeanalysisofbreastcancerbrainmetastasestreatedwithtrastuzumabderuxtecan AT robertacaputo reallifeoutcomeanalysisofbreastcancerbrainmetastasestreatedwithtrastuzumabderuxtecan AT simonapisegna reallifeoutcomeanalysisofbreastcancerbrainmetastasestreatedwithtrastuzumabderuxtecan AT simonescagnoli reallifeoutcomeanalysisofbreastcancerbrainmetastasestreatedwithtrastuzumabderuxtecan AT francescopantano reallifeoutcomeanalysisofbreastcancerbrainmetastasestreatedwithtrastuzumabderuxtecan AT giulianadauria reallifeoutcomeanalysisofbreastcancerbrainmetastasestreatedwithtrastuzumabderuxtecan AT palmafedele reallifeoutcomeanalysisofbreastcancerbrainmetastasestreatedwithtrastuzumabderuxtecan AT agnesefabbri reallifeoutcomeanalysisofbreastcancerbrainmetastasestreatedwithtrastuzumabderuxtecan AT claudiovernieri reallifeoutcomeanalysisofbreastcancerbrainmetastasestreatedwithtrastuzumabderuxtecan AT michelapalleschi reallifeoutcomeanalysisofbreastcancerbrainmetastasestreatedwithtrastuzumabderuxtecan AT luisacarbognin reallifeoutcomeanalysisofbreastcancerbrainmetastasestreatedwithtrastuzumabderuxtecan AT gianluigiferretti reallifeoutcomeanalysisofbreastcancerbrainmetastasestreatedwithtrastuzumabderuxtecan AT elenadimonte reallifeoutcomeanalysisofbreastcancerbrainmetastasestreatedwithtrastuzumabderuxtecan AT idaparis reallifeoutcomeanalysisofbreastcancerbrainmetastasestreatedwithtrastuzumabderuxtecan AT francescopavese reallifeoutcomeanalysisofbreastcancerbrainmetastasestreatedwithtrastuzumabderuxtecan AT ornellagarrone reallifeoutcomeanalysisofbreastcancerbrainmetastasestreatedwithtrastuzumabderuxtecan AT antoniofranco reallifeoutcomeanalysisofbreastcancerbrainmetastasestreatedwithtrastuzumabderuxtecan AT michelinodelaurentiis reallifeoutcomeanalysisofbreastcancerbrainmetastasestreatedwithtrastuzumabderuxtecan AT gianlucafranceschini reallifeoutcomeanalysisofbreastcancerbrainmetastasestreatedwithtrastuzumabderuxtecan AT giovanniscambia reallifeoutcomeanalysisofbreastcancerbrainmetastasestreatedwithtrastuzumabderuxtecan AT dianagiannarelli reallifeoutcomeanalysisofbreastcancerbrainmetastasestreatedwithtrastuzumabderuxtecan AT riccardomasetti reallifeoutcomeanalysisofbreastcancerbrainmetastasestreatedwithtrastuzumabderuxtecan AT andreabotticelli reallifeoutcomeanalysisofbreastcancerbrainmetastasestreatedwithtrastuzumabderuxtecan |